HomeCompareETTX vs EPRT

ETTX vs EPRT: Dividend Comparison 2026

ETTX yields 91.32% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ETTX wins by $2.65M in total portfolio value
10 years
ETTX
ETTX
● Live price
91.32%
Share price
$2.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.71M
Annual income
$860,660.59
Full ETTX calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — ETTX vs EPRT

📍 ETTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodETTXEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ETTX + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ETTX pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ETTX
Annual income on $10K today (after 15% tax)
$7,762.56/yr
After 10yr DRIP, annual income (after tax)
$731,561.50/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, ETTX beats the other by $720,646.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ETTX + EPRT for your $10,000?

ETTX: 50%EPRT: 50%
100% EPRT50/50100% ETTX
Portfolio after 10yr
$1.39M
Annual income
$436,750.66/yr
Blended yield
31.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

ETTX
Analyst Ratings
5
Buy
4
Hold
Consensus: Buy
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ETTX buys
0
EPRT buys
0
No recent congressional trades found for ETTX or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricETTXEPRT
Forward yield91.32%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$2.71M$63.4K
Annual income after 10y$860,660.59$12,840.73
Total dividends collected$2.40M$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ETTX vs EPRT ($10,000, DRIP)

YearETTX PortfolioETTX Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$19,832$9,132.42$11,205$505.18+$8.6KETTX
2$38,148$16,926.92$12,672$682.46+$25.5KETTX
3$71,247$30,428.85$14,490$930.48+$56.8KETTX
4$129,347$53,112.88$16,786$1,282.69+$112.6KETTX
5$228,518$90,117.05$19,753$1,791.56+$208.8KETTX
6$393,309$148,794.86$23,677$2,541.64+$369.6KETTX
7$660,182$239,341.26$29,008$3,672.99+$631.2KETTX
8$1,081,855$375,459.71$36,463$5,425.08+$1.05METTX
9$1,732,607$575,022.24$47,238$8,221.57+$1.69METTX
10$2,714,550$860,660.59$63,385$12,840.73+$2.65METTX

ETTX vs EPRT: Complete Analysis 2026

ETTXStock

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Full ETTX Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this ETTX vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ETTX vs SCHDETTX vs JEPIETTX vs OETTX vs KOETTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.